{"entity":{"id":"ep0031","kind":"drug","name":"EP0031","aka":[],"tldr":"EP0031 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for non-small-cell lung cancer, aimed at RET.","summary":"EP0031 is a small-molecule drug developed by Ellipses Pharma. Its target is RET (the sponsor names RET). ClinicalTrials.gov describes the intervention as: EP0031 is a potent next-generation selective RET-inhibitor (SRI). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05443126, plans to enrol 265 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of EP0031","url":"https://clinicaltrials.gov/search?intr=EP0031"},{"label":"Sponsor page","url":"https://www.ellipses.life"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["ret"],"drugs":[],"companies":["ellipses-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05443126"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"Small-molecule drug directed at RET, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ep0031/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/"}],"company":[{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/"}],"trial":[{"id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","route":"/trials/nct05443126/"}]}}